Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders: Workshop Summary (2015)

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

C Registered Attendees Lauriaselle Afanador Carolyn Asbury University of Maryland The Dana Foundation School of Medicine Dan Barnes Neeraj Agarwal FamilyWize Community National Eye Institute Service Partnership Thompson Akwo Melissa Bartlett Health Consulting Genzyme Corporation International Heather Bonsiero Jeff Allen Spectrum Friends of Cancer Research Lizbet Boroughs Margaret Anderson American Psychiatric FasterCures Association Megan Anderson Marc Boutin CRD Associates National Health Council Robert Armitage Linda Brady Eli Lilly and Company National Institute of Mental Health Bruce Artim Eli Lilly and Company Neil Buckholtz National Institute on Aging 79 

80 FINANCIAL INCENTIVES Rosa Canet-Aviles Diane Dorman Foundation for the National National Organization for Institutes of Health Rare Disorders Garry Carneal Cynthia Duggan The Kennedy Forum The New York Academy of Sciences C. Thomas Caskey Baylor College of Medicine William Emmet The Kennedy Forum Jingyan Chen Genentech Alfred Engelberg The Engelberg Foundation Lauren Chiarello National Multiple Sclerosis Cartier Esham Society Biotechnology Industry Organization Dennis Choi Stony Brook University Brendan Fairfield Next Chapter, LLC Stacy Coen Genzyme Corporation Lisa Feng FasterCures Timothy Coetzee National Multiple Sclerosis William Fisher Society Harvard Law School Adelina Comas-Herrera Brian Fiske London School of Economics The Michael J. Fox and Political Science Foundation for Parkinson’s Research Jacqueline Corrigan-Curay National Institutes of Health Stephen Fried Columbia University Zimmer Danna Graduate School of Center for Biomolecular Journalism Therapeutics Sara Froelich Safiyya Dharssi Genzyme Corporation Pfizer Inc. 

APPENDIX C 81 Miriam Godwin Maureen Japha Genentech FasterCures Nirupa Goel Janet Jenkins-Showalter National Institutes of Health Genentech Walter Greenleaf Stephen Johnson Pear Therapeutics One Mind Christina Hamilton Jeffrey Jonas The lymphangioleiomyomatosis SAGE Therapeutics Inc. (LAM) Foundation Dorothy Jones-Davis Michelle Harris-Love Foundation for the National MedStar National Institutes of Health Rehabilitation Hospital Steven Kaminsky Ramona Hicks International Rett Syndrome One Mind Foundation Richard Hodes Patrick Kennedy National Institute on Aging One Mind and The Kennedy Forum Stuart Hoffman Department of Veterans Aaron Kesselheim Affairs Harvard Medical School and Brigham and Women’s Anna Husain Hospital Threespot Bruce Kinon Steven Hyman Lundbeck LLC, USA Broad Institute of Massachusetts Institute of Walter Koroshetz Technology and Harvard National Institute of University Neurological Disorders and Stroke 

82 FINANCIAL INCENTIVES Kara Kukfa Heddie Martynowicz The Kennedy Forum Janssen Research & Development, LLC Beth Lange Personal Care Products Bonnie Weiss McLeod Council Cooley, LLP Gardiner Lapham David Meeker Citizens United for Research Genzyme, a Sanofi Company in Epilepsy Les Meyer Patroski Lawson Self-Employed Lundbeck LLC, USA Robert Meyer Jay Lombard University of Virginia School Genomind of Medicine Alex London Richard Mohs Carnegie Mellon University Eli Lilly and Company Raj Long Meghan Mott The Bill & Melinda Gates National Institute of Foundation Neurological Disorders and Stroke Roger Longman Real Endpoints Amy Muhlberg PWR Ashley Lusk Threespot Bernard H. Munos Innothink Center for Research Gail Maderis in Biomedical Innovation; BayBio FasterCures Nicholas Manetto Anh Nguyen FaegreBD Consulting U.S. Senate HELP Committee Bruce Margetich Mary O’Donovan FamilyWize Community BioMarin Pharmaceutical Inc. Service Partnership 

APPENDIX C 83 Michele M. Oshman Robert Ring Eli Lilly and Company Autism Speaks Jennifer Palute Diane Robertson Parkinson’s Action Network PWR Diana Pankevich Rhonda Robinson Beale American Association for the Blue Cross of Idaho Advancement of Science Michael Rogawski Steven Paul University of California, Weill Cornell Medical Davis; American Society College; Voyager for Experimental Therapeutics Neurotherapeutics Nicky Penttila Benjamin Roin Dana Foundation Massachusetts Institute of Technology; Sloan School Matthew Peterson of Management PWR Edward F. Rover William Z. Potter Charles A. Dana Foundation; American College of Dana Alliance for Brain Neuropsychopharmacology; Initiatives National Institute of Mental Health Kevin Roy Autism Speaks Rana Quraishi University of Maryland, Katie Sale Baltimore American Brain Coalition Ameet Sarpatwari Arti Rai Harvard Medical School and Duke University School of Brigham and Women’s Law Hospital Peter Reczek Todd Sherer National Institutes of Health The Michael J. Fox Foundation for Parkinson’s Kiran Reddy Research Biogen Idec 

84 FINANCIAL INCENTIVES David Shurtleff Timothy Swope National Center for FasterCures Complementary and Integrative Health William Thies Alzheimer’s Association Phil Skolnick National Institute on Drug Ted Thompson Abuse Parkinson’s Action Network Maryann Smith Steve Tremitiere Participant FamilyWize Community Service Partnership Andrew Sperling National Alliance on Mental Peter Ubel Health Duke University Stuart Spielman Jeffrey Valliere Autism Speaks Threespot Maike Stenull George Vradenburg Johnson & Johnson USAgainstAlzheimer’s Laurie Stepanek Hao Wang American University National Institute of Neurological Disorders and Melissa Stevens Stroke FasterCures Philip Wang Evelyn Strauss National Institute of Mental Freelance Health V. S. Subrahmanian Gemma Weiblinger University of Maryland National Institute of Mental Health Paul Summergrad Tufts University School of Cole Werble Medicine; American The RPM Report Psychiatric Association 

APPENDIX C 85 Samantha White National Institute of Neurological Disorders and Stroke David Wholley Foundation for the National Institutes of Health David Wierz OCI, LLC Ken Wilmarth PWR Andrew Womack Genentech Janet Woodcock Food and Drug Administration Winifred Wu Strategic Regulatory Partners, LLC Jerome Wujek National Eye Institute Sally Young Lundbeck, LLC Stevin Zorn Lundbeck Research USA, Inc.